This research is being done to learn if a new type of haploidentical transplantation using TCR alpha beta and CD19 depleted stem cell graft from the donor is safe and effective to treat the patient's underlying condition. This study will use stem cells obtained via peripheral blood or bone marrow from parent or other half-matched family member donor. These will be processed through a special device called CliniMACS, which is considered investigational.
Cerebrovascular accident lasting longer than 24 hours
Impaired neuropsychological function with abnormal brain MRI/MRA
Patients with frequent (≥ 3 per year for preceding 2 years) painful vaso-occlusive episodes
Recurrent (≥ 3 in lifetime) acute chest syndrome events which have necessitated erythrocyte transfusion therapy
Participants who have an HLA-matched sibling who is able and willing to donate bone marrow. Patients with a HLA-matched unrelated donors are not excluded.
Pregnant or breastfeeding females.
Patient has HIV or uncontrolled fungal, bacterial or viral infections.
Patient has received prior solid organ transplant.
Single group
Haploidentical Hematopoietic Cell Transplantation
Biological/VaccineTCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
Incidence of successful donor engraftment
The incidence of engraftment at day 100 will be described based on donor chimerism in the whole blood and or fractions sorted for T-cell and myeloid subsets. The donor chimerism will be scored as autologous reconstitution (\< 5% donor), mixed chimerism (5-49%=low mixed, 50-95%=high mixed), \> 95%=full donor chimerism.
Overall survival and Event-free survival
Overall survival is defined as the time of enrollment to death from any cause or last follow up. Event-free survival is defined as the time of enrollment to death, primary or secondary graft failure, graft failure necessitating a second HCT procedure, DLI or stem cell boost given for treatment of falling chimerism, or disease recurrence
Kinetics of neutrophil and platelet engraftment
Neutrophil engraftment defined as absolute neutrophil count ≥500/μL for 3 consecutive measurements on different days and platelet engraftment defined as sustained platelet count \>20,000/μL and \>50,000//μL with no platelet transfusions in the preceding seven days.
Transplant-related mortality
Rate of transplant-related mortality
Acute grade II-IV GvHD and Chronic GvHD
Incidence and severity of acute and chronic graft versus host disease
Click on the lead sponsor to view all of their trials.
